DC-CHOL

Description

DC-Chol is a cationic cholesterol derivative. DC-Chol, as a component of lipoplexes with DOPE , has been used for transfection of mRNA into A549 cells without affecting cell viability. Incubation of DC-chol/DOPE liposomes or lipoplexes with human whole blood has no effect on neutrophil elastase or β-thromboglobulin levels or the number of platelets and red and white blood cells, indicating hemocompatibility. DC-Chol has also been widely used in the synthesis of liposomes for the delivery of siRNA, DNA, and chemotherapeutic agents into cells and mice.

Uses

This cationic cholesterol derivative forms liposomes with L-α-phosphatidylethanolamine, dioleoyl, that efficiently transfect mammalian cell lines.

Uses

DC-Cholesterol HCl is suitable:

• for the preparation of ultrasound cationic microbubbles
• to prepare liposomes
• for the preparation of L-glutathione (GSH), loaded proliposomes

General Description

DC-Cholesterol HCl is a sterol-based transfection reagent.

Biochem/physiol Actions

DC-Cholesterol is an effective transfection agent and a liposome reagent. Liposome of DC-Cholesterol with dioleoylphosphatidylethanolamine (DOPE) are efficient for DNA transfection. It imparts positive surface charge to the microbubbles for ultra sound based transfection of clustered regularly interspaced short palindromic repeats (CRISPRs).

storage

Store at -20°C

References

[1] TATJANA MICHEL. Cationic Nanoliposomes Meet mRNA: Efficient Delivery of Modified mRNA Using Hemocompatible and Stable Vectors for Therapeutic Applications.[J]. Molecular Therapy. Nucleic Acids, 2017, 8: 459-468. DOI: 10.1016/j.omtn.2017.07.013
[2] JIE GAO . Lyophilized HER2-specific PEGylated immunoliposomes for active siRNA gene silencing[J]. Biomaterials, 2010, 31 9: Pages 2655-2664. DOI: 10.1016/j.biomaterials.2009.11.112
[3] RAN ZHANG. Codelivery of paclitaxel and small interfering RNA by octadecyl quaternized carboxymethyl chitosan-modified cationic liposome for combined cancer therapy.[J]. Journal of Biomaterials Applications, 2015, 30 3: 351-360. DOI: 10.1177/0885328215579297
[4] YING MEN. The efficacy of mitochondrial targeting antiresistant epirubicin liposomes in treating resistant leukemia in animals.[J]. International Journal of Nanomedicine, 2011: 3125-3137. DOI: 10.2147/ijn.s24847
[5] X XING. Safety studies of the intraperitoneal injection of E1A–liposome complex in mice[J]. Gene Therapy, 1997, 4 3: 238-243. DOI: 10.1038/sj.gt.3300376